Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN DIEGO , June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

  Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry.  Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses. SAN DIEGO , June 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S. SAN DIEGO , June 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological

Poster details data from aTyr’s pre-clinical, domain specific Neuropilin-2 (NRP2) antibody program highlighting therapeutic potential in triple-negative breast cancer SAN DIEGO , May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery

Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO , May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological

Management to host conference call and webcast on May 12th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways,

Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflammatory conditions SAN

SAN DIEGO , April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its

Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO , March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO , March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.